2020
MON-593 Single-Dose Effects of Anti-Obesity Drugs on Human Basal Metabolic Rate
Israni N, Cassimatis T, Fletcher L, Leitner B, Duckworth C, Hattenbach J, Bell S, McGehee S, Brychta R, Courville A, Bernstein S, Muniyappa R, Reitman M, Cypess A, Chen K. MON-593 Single-Dose Effects of Anti-Obesity Drugs on Human Basal Metabolic Rate. Journal Of The Endocrine Society 2020, 4: mon-593. PMCID: PMC7209218, DOI: 10.1210/jendso/bvaa046.366.Peer-Reviewed Original ResearchAnti-obesity drugsHeart rateBasal metabolic rateEnergy expenditureRespiratory quotientSympathetic nervous system activityRandomized cross-over studyPrespecified primary outcomeSingle-dose effectsDrug-naïve subjectsCross-over studyClinical research unitNervous system activityWhole-room indirect calorimeterLong-term interventionsSelf-reported hungerSecondary outcomesArterial pressureHunger scoresPrimary outcomeWashout periodAppetite suppressionChronic useSingle doseAcute effects
2018
Physiological Responses to Daily Use of Beta-Three Adrenergic Receptor Agonist, Mirabegron
O'MARA A, CYPESS A, CERO C, JOHNSON J, LINDERMAN J, LEITNER B, FLETCHER L, BRYCHTA R, KAPURIA D, MCGEHEE S, ROTMAN Y. Physiological Responses to Daily Use of Beta-Three Adrenergic Receptor Agonist, Mirabegron. Diabetes 2018, 67 DOI: 10.2337/db18-1146-p.Peer-Reviewed Original ResearchRate-pressure productNon-esterified fatty acidsBrown adipose tissueSerum non-esterified fatty acidsCold exposureWeeks of treatmentBAT metabolic activityHealthy female volunteersAdrenergic receptor agonistPET/CTΒ3-adrenergic receptor agonistDaily mirabegronCardiovascular stimulationPrimary endpointSecondary endpointsChronic treatmentBAT volumeLiver steatosisMetabolic healthPressure productTreatment optionsInsulin sensitivityPharmacotherapeutic approachesReceptor agonistAcute effects